Long-chain-aldehyde dehydrogenase
Fatty aldehyde dehydrogenase (or Long-chain-aldehyde dehydrogenase) is an aldehyde dehydrogenase enzyme that in human is encoded in the ALDH3A2 gene on chromosome 17. Aldehyde dehydrogenase enzymes function to remove toxic aldehydes that are generated by the metabolism of alcohol and by lipid peroxidation.
Structure
The ALDH3A2 belongs to the aldehyde dehydrogenase superfamily and is a membrane-associated protein typically containing 485 residues. The mature protein functions as a dimer. The structure was resolved using X-ray crystallography at 2.1 Angstrom resolution. It contains an element in the C-terminal region referred to as a "gatekeeper" helix, which is adjacent to the membrane-anchored transmembrane domain and the catalytic core. The gatekeeper helix appears to control access of molecular substrates to the catalytic core and allows efficient transit between membranes and catalytic sites.[5]
Function
ALDH3A2 catalyzes the oxidation of long-chain aliphatic aldehydes into fatty acids. It is known to act on a variety of both saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length, as well as dihydrophytal, a 20-carbon branched chain aldehyde.[6] It requires NAD+ as a co-factor. The encoded enzyme is responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid. ALD3H2 is expressed in the human liver and has been found to localize the microsome fraction inside the cell.[7]
At least two alternative splicing isofroms of ALDH3A2 are known to exist. The alternative transcript differs by an additional exon and anchors differently to the endoplasmic reticulum vs. the peroxisome [8]
Clinical significance
Mutations and deletions of in the ALDH3A2 gene have been widely associated with the autosomal recessive Sjögren-Larsson syndrome, an autosomal recessive neurocutaneous disease.[9] Multiple mutations have been found in different families, including those that molecularly disrupts the protein dimerization interface or reduces mRNA stability. Absence or insufficiency of ALDH3A2 protein products in mutant cells are known to cause abnormal metabolism of sphingosine 1-phosphate to ether-linked glycerolipids and the abnormal accumulation of lipid precursors.
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000072210 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000010025 - Ensembl, May 2017
- ↑ "Human PubMed Reference:".
- ↑ "Mouse PubMed Reference:".
- ↑ Keller MA, Zander U, Fuchs JE, Kreutz C, Watschinger K, Mueller T, Golderer G, Liedl KR, Ralser M, Kräutler B, Werner ER, Marquez JA (2014). "A gatekeeper helix determines the substrate specificity of Sjögren-Larsson Syndrome enzyme fatty aldehyde dehydrogenase". Nat Commun. 5: 4439. PMC 4109017
. PMID 25047030. doi:10.1038/ncomms5439. - ↑ Kelson TL, Secor McVoy JR, Rizzo WB (1997). "Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization". Biochim. Biophys. Acta. 1335 (1-2): 99–110. PMID 9133646. doi:10.1016/s0304-4165(96)00126-2.
- ↑ Kelson TL, Secor McVoy JR, Rizzo WB (1997). "Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization". Biochim. Biophys. Acta. 1335 (1-2): 99–110. PMID 9133646. doi:10.1016/s0304-4165(96)00126-2.
- ↑ Rogers GR, Markova NG, De Laurenzi V, Rizzo WB, Compton JG (1997). "Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH)". Genomics. 39 (2): 127–35. PMID 9027499. doi:10.1006/geno.1996.4501.
- ↑ Nakahara K, Ohkuni A, Kitamura T, Abe K, Naganuma T, Ohno Y, Zoeller RA, Kihara A (2012). "The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway". Mol. Cell. 46 (4): 461–71. PMID 22633490. doi:10.1016/j.molcel.2012.04.033.
Further reading
- long-chain-aldehyde dehydrogenase at the US National Library of Medicine Medical Subject Headings (MeSH)